Developer docs
API playgroundTry for free, no card

Search company profiles

Ayala Pharmaceuticals

Full company profile

uuid00031as

Namestring
Ayala Pharmaceuticals
Legal namestring
Ayala Pharmaceuticals, Inc.
Websiteurl
ayalapharma.com
Company typeenum
Public
Founded yearint
2023
Descriptiontext

Ayala Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing and commercializing small molecule therapeutics for rare tumors and aggressive cancers. The company's lead candidates were gamma-secretase inhibitors AL102 and AL101, with AL102 in Phase 3 clinical development for desmoid tumors — a rare oncology indication with limited treatment options. The company also operated a Listeria monocytogenes-based immunotherapy platform for cancer treatment. Its target segment was patients with desmoid tumors and other rare or aggressive cancers, addressing unmet medical needs, though it had no commercial product on market during its operating life.

The company operated with no commercial product revenue and was unprofitable, reporting approximately $3.24 million in revenue while carrying negative net income. It was incorporated in Delaware, listed on Nasdaq under the symbol ADXS (also referenced as AYLA), and operated with 11–50 employees from Wilmington, Delaware. The entity traded under the Ayala Pharmaceuticals name was formed through the January 2023 merger of Advaxis Inc. with a pre-existing Delaware-incorporated Ayala Pharmaceuticals; the combined entity assumed the Ayala name and pursued a Nasdaq uplisting. Three disclosed funding rounds totaling $72 million (2018: $17M; 2019: $30M; 2021: $25M) supported the clinical pipeline through its operating life. Investors included Novartis (as 2019 lead), aMoon Fund, Harel Insurance and Financial, Israel Biotech Fund, SBI Japan-Israel Innovation Fund, Redmile Group, and Sio Capital Management.

Ayala's strategic trajectory ended in wind-down rather than expansion. In Q1 2024, the lead assets AL102 and AL101 were divested to Immunome, Inc.; in May 2024, the company filed Form 15-12G to deregister its securities with the SEC; in April 2025, the Listeria-based immunotherapy platform was transferred to OS Therapies in exchange for 4.8 million shares (which eliminated $20 million in milestone payments owed to Ayala); and on February 9, 2026, Ayala completed liquidation of its OS Therapies common stock and dissolved, with no operating entity remaining.

Short descriptiontext

Ayala Pharmaceuticals was a clinical-stage biopharmaceutical company that developed gamma-secretase inhibitors (AL102, AL101) and a Listeria monocytogenes-based immunotherapy platform targeting rare tumors and aggressive cancers, including desmoid tumors. The company dissolved in February 2026 after divesting all assets.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWilmington, United States
HQ citystring
Wilmington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical-stage oncology therapeutics, small molecule drug development, gamma-secretase inhibitors, rare tumor treatments, cancer immunotherapy platform
Industry2 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Clinical-stage Oncology Pharmaceuticals
No data
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ayala Pharmaceuticals was a clinical-stage biopharmaceutical company that developed small molecule oncology drug candidates for rare tumors and aggressive cancers. Its lead program AL102 was in Phase 3 clinical trials for desmoid tumors, with AL101 and BST-236 as additional pipeline assets. The company also operated a proprietary listeria monocytogenes-based cancer immunotherapy platform transferred to OS Therapies in April 2025.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • AL102 was in Phase 3 clinical trials for desmoid tumors
Product overview1 text field

Ayala Pharmaceuticals was a clinical-stage oncology company focused on developing treatments for rare tumors and aggressive cancers. The company operated with a pipeline of investigational drug candidates including AL102 (Phase 3 for desmoid tumors), AL101, and BST-236. Following the completion of a merger with Advaxis Inc. in January 2023, the combined entity operated under the Ayala Pharmaceuticals name. The company's pipeline assets (AL102 and AL101) were subsequently acquired by Immunome, Inc. in Q1 2024. Ayala Pharmaceuticals has since dissolved, with its listeria-based immunotherapy platform transferred to OS Therapies in April 2025.

Product and service4 records
1AL102
CategoryDrug candidate (gamma-secretase inhibitor)
Description

Investigational gamma-secretase inhibitor therapy for desmoid tumors that was in Phase 3 clinical development. The program was acquired by Immunome, Inc. in Q1 2024.

2AL101
CategoryDrug candidate (gamma-secretase inhibitor)
Description

Investigational gamma-secretase inhibitor drug candidate acquired by Immunome, Inc. in Q1 2024 alongside AL102.

3BST-236
CategoryDrug candidate
Description

Treatment candidate referenced in Ayala Pharmaceuticals company communications; inquiries directed to Sarit Steinberg.

4Listeria monocytogenes-based cancer immunotherapy platform
CategoryCancer immunotherapy platform
Description

Proprietary Listeria monocytogenes-based immunotherapy platform for cancer treatment; clinical, preclinical, and intellectual property assets were transferred to OS Therapies in April 2025 in exchange for 4.8 million shares.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-01
Description

OS Therapies acquired the listeria monocytogenes immunotherapy platform from Ayala Pharmaceuticals in April 2025. The acquisition included all clinical, preclinical, and intellectual property assets. OS Therapies issued 4.8 million shares to Ayala as consideration. This transaction eliminated $20 million in milestone payments for Ayala.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-20
Description

Advaxis Inc. completed its merger with Ayala Pharmaceuticals. The merged entity operated under the name Ayala Pharmaceuticals and focused on developing treatments for rare tumors and aggressive cancers, aiming to uplist to Nasdaq.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage oncology biopharma that acquired Ayala's lead assets AL102 and AL101 in Q1 2024. Directly comparable as a clinical-stage rare-oncology developer that now owns Ayala's former desmoid tumor and rare-cancer programs.

TypeDirect peer
Description

Oncology biopharma that acquired Ayala's listeria monocytogenes immunotherapy platform in April 2025. Comparable as a clinical-stage oncology developer working with listeria-based and rare-tumor immunotherapy assets.

TypeDirect peer
Description

Commercial-stage rare-oncology biopharma whose lead asset (nirogacestat) targets desmoid tumors — the same indication Ayala's AL102 was pursuing. Highly comparable target indication, patient population, and rare-tumor commercial model.

TypeDirect peer
Description

Rare-tumor-focused oncology biopharma developing kinase inhibitors for cancers with limited treatment options. Comparable as a clinical-to-commercial rare oncology specialist with overlapping therapeutic positioning.

TypeEmerging player
Description

Emerging clinical-stage developer of gamma-secretase inhibitors and other oncology candidates. Direct mechanistic overlap with Ayala's AL102/AL101 program.

TypeDirect peer
Description

Clinical-stage oncology company developing treatments for rare cancers, including listeria-based immunotherapy programs. Comparable via shared listeria immunotherapy modality and rare-cancer focus.

7Forma Therapeutics
TypeDirect peer
Description

Clinical-stage biopharma focused on rare hematologic diseases and cancers. Comparable as a small-cap, clinical-stage rare-disease oncology developer.

TypeDirect peer
Description

Clinical-stage oncology company developing small-molecule therapeutics targeting DNA damage response pathways. Comparable as a small-cap clinical-stage oncology specialist with a similar capital profile.

TypeBroad incumbent
Description

Larger clinical-to-commercial oncology biopharma developing antibody-based therapeutics. Comparable as a public clinical-stage oncology developer with overlapping rare-cancer and aggressive-tumor programs, but at greater scale.

TypeEmerging player
Description

Clinical-stage biotech using AI-driven discovery to advance rare-disease and oncology candidates. Comparable as a small-cap clinical-stage developer targeting rare tumors with platform-driven R&D.

Market position
Strengths2 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ayala Pharmaceuticals

Clinical-stage Oncology Pharmaceuticalsayalapharma.com

Ayala Pharmaceuticals was a clinical-stage biopharmaceutical company that developed gamma-secretase inhibitors (AL102, AL101) and a Listeria monocytogenes-based immunotherapy platform targeting rare tumors and aggressive cancers, including desmoid tumors. The company dissolved in February 2026 after divesting all assets.

What Ayala Pharmaceuticals does

Ayala Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing and commercializing small molecule therapeutics for rare tumors and aggressive cancers. The company's lead candidates were gamma-secretase inhibitors AL102 and AL101, with AL102 in Phase 3 clinical development for desmoid tumors — a rare oncology indication with limited treatment options. The company also operated a Listeria monocytogenes-based immunotherapy platform for cancer treatment. Its target segment was patients with desmoid tumors and other rare or aggressive cancers, addressing unmet medical needs, though it had no commercial product on market during its operating life.

The company operated with no commercial product revenue and was unprofitable, reporting approximately $3.24 million in revenue while carrying negative net income. It was incorporated in Delaware, listed on Nasdaq under the symbol ADXS (also referenced as AYLA), and operated with 11–50 employees from Wilmington, Delaware. The entity traded under the Ayala Pharmaceuticals name was formed through the January 2023 merger of Advaxis Inc. with a pre-existing Delaware-incorporated Ayala Pharmaceuticals; the combined entity assumed the Ayala name and pursued a Nasdaq uplisting. Three disclosed funding rounds totaling $72 million (2018: $17M; 2019: $30M; 2021: $25M) supported the clinical pipeline through its operating life. Investors included Novartis (as 2019 lead), aMoon Fund, Harel Insurance and Financial, Israel Biotech Fund, SBI Japan-Israel Innovation Fund, Redmile Group, and Sio Capital Management.

Ayala's strategic trajectory ended in wind-down rather than expansion. In Q1 2024, the lead assets AL102 and AL101 were divested to Immunome, Inc.; in May 2024, the company filed Form 15-12G to deregister its securities with the SEC; in April 2025, the Listeria-based immunotherapy platform was transferred to OS Therapies in exchange for 4.8 million shares (which eliminated $20 million in milestone payments owed to Ayala); and on February 9, 2026, Ayala completed liquidation of its OS Therapies common stock and dissolved, with no operating entity remaining.

Ayala Pharmaceuticals firmographics

Firmographics
Name
Ayala Pharmaceuticals
Legal name
Ayala Pharmaceuticals, Inc.
Website
https://ayalapharma.com
Company type
Public
Founded year
2023
Operating status
Closed
Headcount range
11–50 employees
Short description
Ayala Pharmaceuticals was a clinical-stage biopharmaceutical company that developed gamma-secretase inhibitors (AL102, AL101) and a Listeria monocytogenes-based immunotherapy platform targeting rare tumors and aggressive cancers, including desmoid tumors. The company dissolved in February 2026 after divesting all assets.
Ownership category
akta.pro rank

Ayala Pharmaceuticals industry classification

Industry
Product category
Clinical-stage Oncology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)

Keywords

  • Clinical-stage oncology therapeutics
  • Small molecule drug development
  • Gamma-secretase inhibitors
  • Rare tumor treatments
  • Cancer immunotherapy platform

Where Ayala Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Wilmington
HQ country
United States
HQ region
North America

Markets served

Ayala Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Ayala Pharmaceuticals product offering

Product offering

Core offering

Ayala Pharmaceuticals was a clinical-stage biopharmaceutical company that developed small molecule oncology drug candidates for rare tumors and aggressive cancers. Its lead program AL102 was in Phase 3 clinical trials for desmoid tumors, with AL101 and BST-236 as additional pipeline assets. The company also operated a proprietary listeria monocytogenes-based cancer immunotherapy platform transferred to OS Therapies in April 2025.

Product overview

Ayala Pharmaceuticals was a clinical-stage oncology company focused on developing treatments for rare tumors and aggressive cancers. The company operated with a pipeline of investigational drug candidates including AL102 (Phase 3 for desmoid tumors), AL101, and BST-236. Following the completion of a merger with Advaxis Inc. in January 2023, the combined entity operated under the Ayala Pharmaceuticals name. The company's pipeline assets (AL102 and AL101) were subsequently acquired by Immunome, Inc. in Q1 2024. Ayala Pharmaceuticals has since dissolved, with its listeria-based immunotherapy platform transferred to OS Therapies in April 2025.

Differentiator

Problem solved

Functional benefit

Products and services

  • AL102 Investigational gamma-secretase inhibitor therapy for desmoid tumors that was in Phase 3 clinical development. The program was acquired by Immunome, Inc. in Q1 2024.
  • AL101 Investigational gamma-secretase inhibitor drug candidate acquired by Immunome, Inc. in Q1 2024 alongside AL102.
  • BST-236 Treatment candidate referenced in Ayala Pharmaceuticals company communications; inquiries directed to Sarit Steinberg.
  • Listeria monocytogenes-based cancer immunotherapy platform Proprietary Listeria monocytogenes-based immunotherapy platform for cancer treatment; clinical, preclinical, and intellectual property assets were transferred to OS Therapies in April 2025 in exchange for 4.8 million shares.

Quantifiable outcome

  • AL102 was in Phase 3 clinical trials for desmoid tumors

Companies that use Ayala Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles1 record

Ayala Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Ayala Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • OS TherapiescoreStrategic or Co-development Partner · 1 April 2025OS Therapies acquired the listeria monocytogenes immunotherapy platform from Ayala Pharmaceuticals in April 2025. The acquisition included all clinical, preclinical, and intellectual property assets. OS Therapies issued 4.8 million shares to Ayala as consideration. This transaction eliminated $20 million in milestone payments for Ayala.
  • Advaxis Inc.coreStrategic or Co-development Partner · 20 January 2023Advaxis Inc. completed its merger with Ayala Pharmaceuticals. The merged entity operated under the name Ayala Pharmaceuticals and focused on developing treatments for rare tumors and aggressive cancers, aiming to uplist to Nasdaq.

Scale indicators1 record

Recent moves7 records

Expansion highlights2 records

Ayala Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Immunome: Clinical-stage oncology biopharma that acquired Ayala's lead assets AL102 and AL101 in Q1 2024. Directly comparable as a clinical-stage rare-oncology developer that now owns Ayala's former desmoid tumor and rare-cancer programs.
  • OS Therapies: Oncology biopharma that acquired Ayala's listeria monocytogenes immunotherapy platform in April 2025. Comparable as a clinical-stage oncology developer working with listeria-based and rare-tumor immunotherapy assets.
  • SpringWorks Therapeutics: Commercial-stage rare-oncology biopharma whose lead asset (nirogacestat) targets desmoid tumors — the same indication Ayala's AL102 was pursuing. Highly comparable target indication, patient population, and rare-tumor commercial model.
  • Deciphera Pharmaceuticals: Rare-tumor-focused oncology biopharma developing kinase inhibitors for cancers with limited treatment options. Comparable as a clinical-to-commercial rare oncology specialist with overlapping therapeutic positioning.
  • Salarius Pharmaceuticals: Clinical-stage oncology company developing treatments for rare cancers, including listeria-based immunotherapy programs. Comparable via shared listeria immunotherapy modality and rare-cancer focus.
  • Forma Therapeutics: Clinical-stage biopharma focused on rare hematologic diseases and cancers. Comparable as a small-cap, clinical-stage rare-disease oncology developer.
  • Aprea Therapeutics: Clinical-stage oncology company developing small-molecule therapeutics targeting DNA damage response pathways. Comparable as a small-cap clinical-stage oncology specialist with a similar capital profile.

Emerging players

  • Iterion Therapeutics: Emerging clinical-stage developer of gamma-secretase inhibitors and other oncology candidates. Direct mechanistic overlap with Ayala's AL102/AL101 program.
  • Recursion Pharmaceuticals: Clinical-stage biotech using AI-driven discovery to advance rare-disease and oncology candidates. Comparable as a small-cap clinical-stage developer targeting rare tumors with platform-driven R&D.

Broad incumbents

  • MacroGenics: Larger clinical-to-commercial oncology biopharma developing antibody-based therapeutics. Comparable as a public clinical-stage oncology developer with overlapping rare-cancer and aggressive-tumor programs, but at greater scale.

Market position

Strengths2 records

Weaknesses3 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Ayala Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ayala Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles7 records

Ayala Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ayala Pharmaceuticals M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ayala Pharmaceuticals

What does Ayala Pharmaceuticals do?

Ayala Pharmaceuticals was a clinical-stage biopharmaceutical company that developed small molecule oncology drug candidates for rare tumors and aggressive cancers. Its lead program AL102 was in Phase 3 clinical trials for desmoid tumors, with AL101 and BST-236 as additional pipeline assets. The company also operated a proprietary listeria monocytogenes-based cancer immunotherapy platform transferred to OS Therapies in April 2025.

Is Ayala Pharmaceuticals a public or private company?

Ayala Pharmaceuticals is a public company. It is classified as public and is currently closed.

When was Ayala Pharmaceuticals founded?

Ayala Pharmaceuticals was founded in 2023. It employs 11 to 50 people.

Where is Ayala Pharmaceuticals based?

Ayala Pharmaceuticals is headquartered in Wilmington, United States, in the North America region.

Who are Ayala Pharmaceuticals's main competitors?

Direct peers on record are Immunome, OS Therapies, SpringWorks Therapeutics, Deciphera Pharmaceuticals, Salarius Pharmaceuticals, Forma Therapeutics and Aprea Therapeutics. Emerging players are Iterion Therapeutics and Recursion Pharmaceuticals. MacroGenics is listed as a broad incumbent.

Does Ayala Pharmaceuticals have an API?

No public API is recorded for Ayala Pharmaceuticals.

What industry is Ayala Pharmaceuticals in?

Ayala Pharmaceuticals's product category is Clinical-stage Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAAFAD, Engineered Microbial Therapeutics (synthetic biology, gene circuits). Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ticker ReportCritical Comparison: Ayala Pharmaceuticals (NASDAQ:ADXS) versus Synaptogenix (NASDAQ:TAOX)MarketBeat published a comparative analysis of small-cap healthcare companies Synaptogenix and Ayala Pharmaceuticals, evaluating metrics such as valuation, earnings, profitability, and analyst recommendations. The report highlights that while Synaptogenix has higher earnings, it trades at a lower price-to-earnings ratio compared to Ayala Pharmaceuticals.Defense WorldCritical Review: Ayala Pharmaceuticals (NASDAQ:ADXS) and Nuvo Pharmaceuticals (OTCMKTS:MRVFF)This comparative analysis examines Ayala Pharmaceuticals, a clinical-stage oncology company based in Delaware, and Nuvo Pharmaceuticals, a Canadian pharmaceutical company, across financial metrics including volatility, profitability, and valuation. Nuvo Pharmaceuticals reports significantly higher revenue at $54.98 million compared to Ayala's $3.24 million, though both companies are currently unprofitable with negative net income. The analysis finds Nuvo Pharmaceuticals outperforms Ayala Pharmaceuticals on 6 of 11 comparison factors, including revenue, earnings, and valuation metrics.OstherapiesOS Therapies Provides Corporate UpdateOS Therapies reported positive Phase 2b data for OST-HER2 in osteosarcoma, with 33% responder rate versus 20% in historical control. The company raised $13.1 million and acquired Ayala's Listeria assets, aiming for FDA approval by September 2026. It plans to evaluate OST-HER2 in other HER2-related cancers.Business Wire BlogOS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to PipeOS Therapies agreed to acquire Ayala Pharmaceuticals' listeria monocytogenes-based immuno-oncology programs and IP, including a Phase 2 lung cancer and Phase 1 prostate cancer program. The deal includes $0.5 million cash and $7.5 million in shares, eliminating certain OST-HER2 milestone payments and reducing royalties. OS Therapies expects to submit a BLA for OST-HER2 in osteosarcoma in Q2 2025.American Banking and Market NewsStockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)StockNews.com initiated coverage on Ayala Pharmaceuticals with a sell rating. The stock opened at $0.15, with a market cap of $6.39 million and a P/E of -0.02. The company develops small-molecule therapeutics for rare tumors and aggressive cancers.Pulse 2.0Immunome To Buy AL102 From Ayala Pharmaceuticals, A Phase 3 Asset For Treating Desmoid TumorsImmunome agreed to acquire AL102 from Ayala Pharmaceuticals for $20 million cash and $30 million in stock, plus up to $37.5 million in milestones. AL102 is a gamma secretase inhibitor in Phase 3 for desmoid tumors, with Phase 2 data showing 75% response rates. The deal is subject to Ayala's stockholder approval.GlobeNewswireAyala Pharmaceuticals and Biosight Enter into Definitive Merger AgreementAyala Pharmaceuticals and Biosight entered a definitive merger agreement, combining in an all-stock transaction. The combined company will operate as Ayala Pharmaceuticals, with 55% ownership going to Biosight shareholders and 45% to Ayala shareholders. The deal is expected to close before the end of the third quarter of 2023.ThemiddlemarketAyala Pharmaceuticals Merges with BiosightAyala Pharmaceuticals has merged with Biosight, with the combined entity operating under the name Ayala Pharmaceuticals Inc. This transaction is part of a broader list of corporate acquisitions and mergers reported in the text. The article provides limited detail on the specific financial terms or strategic rationale behind this particular merger.NJBIZAdvaxis completes merger to become Ayala PharmaceuticalsAdvaxis Inc. has completed its merger with Ayala Pharmaceuticals Inc., creating a new entity that will operate under the name Ayala Pharmaceuticals. The combined company will focus on the development and commercialization of Ayala's lead program, AL102, aimed at treating desmoid tumors, and plans to pursue a Nasdaq uplisting, though success is not guaranteed.GlobeNewswireAdvaxis and Ayala Pharmaceuticals Complete MergerAdvaxis and Ayala Pharmaceuticals completed their merger, with the combined entity operating under the name Ayala Pharmaceuticals and focusing on the development of its lead program AL102 for desmoid tumors. The merged company will continue trading on the OTC markets under the symbol ADXS while seeking to uplist to Nasdaq. Leadership roles were assigned to existing executives from Advaxis, including Kenneth A. Berlin as CEO.